0.7812
price down icon2.35%   -0.0188
after-market Handel nachbörslich: .80 0.0188 +2.41%
loading
Schlusskurs vom Vortag:
$0.80
Offen:
$0.8
24-Stunden-Volumen:
746.54K
Relative Volume:
0.07
Marktkapitalisierung:
$32.92M
Einnahmen:
$500.00K
Nettoeinkommen (Verlust:
$-19.45M
KGV:
-0.4133
EPS:
-1.89
Netto-Cashflow:
$-18.22M
1W Leistung:
-11.99%
1M Leistung:
-68.63%
6M Leistung:
-17.77%
1J Leistung:
-38.00%
1-Tages-Spanne:
Value
$0.7567
$0.8001
1-Wochen-Bereich:
Value
$0.6981
$0.9099
52-Wochen-Spanne:
Value
$0.37
$3.65

Imunon Inc Stock (IMNN) Company Profile

Name
Firmenname
Imunon Inc
Name
Telefon
(609) 896-9100
Name
Adresse
997 LENOX DRIVE, LAWRENCEVILLE
Name
Mitarbeiter
25
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
IMNN's Discussions on Twitter

Vergleichen Sie IMNN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
IMNN
Imunon Inc
0.7812 32.92M 500.00K -19.45M -18.22M -1.89
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.16 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
534.91 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.06 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
542.47 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.16 28.51B 3.81B -644.79M -669.77M -6.24

Imunon Inc Aktie (IMNN) Neueste Nachrichten

pulisher
Jun 18, 2025

IMNN Presents Promising Phase 2 OVATION 2 Study Results at ESMO Congress | IMNN Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

IMUNON reports promising ovarian cancer therapy data at ESMO - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

IMUNON Presents Positive Phase 2 Translational Data of - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Breakthrough in Ovarian Cancer Treatment: New Drug Amplifies Immune Response by 62-fold, Phase 3 Trial Begins - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

IMUNON reports durability data for COVID-19 vaccine alternative By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 17, 2025

IMUNON reports durability data for COVID-19 vaccine alternative - Investing.com Australia

Jun 17, 2025
pulisher
Jun 17, 2025

IMNN Showcases Positive Phase 1 Results for DNA Plasmid Vaccine - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ - The Manila Times

Jun 17, 2025
pulisher
Jun 17, 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™ | IMNN Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

IMUNON Reports Six-Month Durability and Manufacturing Benefits of PlaCCine® DNA Vaccine Technology Over mRNA Vaccines, Seeks Strategic Partnership - Nasdaq

Jun 17, 2025
pulisher
Jun 17, 2025

IMUNON Announces PlaCCine® DNA Vaccine Technology Abstract - GlobeNewswire

Jun 17, 2025
pulisher
Jun 17, 2025

IMUNON at ASCO 2025: Changing the micro-tumour environment in advanced ovarian cancer - pharmaphorum

Jun 17, 2025
pulisher
Jun 13, 2025

Imunon Inc. appoints new CFO following termination - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Imunon Inc. appoints new CFO following termination By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Imunon Appoints Kimberly Graper as Interim CFO - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

ImunonTerminates CFO David Gaiero's Service Agreement - MarketScreener

Jun 13, 2025
pulisher
Jun 09, 2025

Why Imunon, Inc. (IMNN) Surged Last Week - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Imunon regains Nasdaq compliance with bid price By Investing.com - Investing.com South Africa

Jun 09, 2025
pulisher
Jun 09, 2025

Imunon Regains Nasdaq Compliance with Bid Price - TipRanks

Jun 09, 2025
pulisher
Jun 09, 2025

Imunon regains Nasdaq compliance with bid price - Investing.com

Jun 09, 2025
pulisher
Jun 08, 2025

Imunon (NASDAQ:IMNN) Raised to Sell at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Top Companies in the NASDAQ by Kalkine Leading Market Performers Today - Kalkine Media

Jun 06, 2025
pulisher
Jun 06, 2025

Equities Analysts Offer Predictions for Imunon Q2 Earnings - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Phase 3 DNA Immunotherapy Developer IMUNON Opens Live Q&A with Investors Next Week - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

IMUNON Announces Data Presented at ASCO Reinforces - GlobeNewswire

Jun 03, 2025
pulisher
Jun 03, 2025

Imunon announces data from Phase 2 OVATION 2 study on IMNN-001 - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

IMNN: Promising Phase 2 Results in Ovarian Cancer Treatment | IMNN Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Imunon CEO says company ‘has never been stronger’ - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

IMNN Advances Cancer Treatment with Promising Phase 2 Results | IMNN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDA - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS | IMNN Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

IMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS - The Manila Times

Jun 02, 2025
pulisher
Jun 02, 2025

Breakthrough Ovarian Cancer Drug Extends Patient Survival by 13 Months in Phase 2 Trial, ASCO Data Shows - Stock Titan

Jun 02, 2025
pulisher
Jun 01, 2025

Should You Buy, Sell, or Hold Shopify Stock in June 2025? - The Globe and Mail

Jun 01, 2025
pulisher
May 31, 2025

IMUNON launches up to $9.75M securities offering - MSN

May 31, 2025
pulisher
May 31, 2025

Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues By Investing.com - Investing.com Canada

May 31, 2025
pulisher
May 30, 2025

Imunon (IMNN) Announces Plans to Offer 22.03 Million Shares | IM - GuruFocus

May 30, 2025
pulisher
May 30, 2025

Imunon Faces Nasdaq Delisting Due to Non-Compliance - TipRanks

May 30, 2025
pulisher
May 30, 2025

Imunon Inc. Faces Nasdaq Delisting Over Compliance Issues - Investing.com

May 30, 2025
pulisher
May 30, 2025

Public market insider selling at TerraVest Industries (TVK) - The Globe and Mail

May 30, 2025
pulisher
May 29, 2025

Imunon, Inc. (IMNN) Raises $3.25M in Private Placement, Eyes $6.5M More - Yahoo Finance

May 29, 2025

Finanzdaten der Imunon Inc-Aktie (IMNN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Imunon Inc-Aktie (IMNN) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Lindborg Stacy
President and CEO
Aug 15 '24
Buy
0.98
25,000
24,500
264,166
Tardugno Michael H
Executive Chairman of Board
Aug 15 '24
Buy
1.03
25,000
25,750
353,346
$20.74
price up icon 0.39%
$35.88
price down icon 0.42%
$21.20
price down icon 0.38%
$97.62
price down icon 3.00%
$107.51
price up icon 0.98%
biotechnology ONC
$245.16
price up icon 1.28%
Kapitalisierung:     |  Volumen (24h):